Pyxis Oncology, Inc.
PYXS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001782223
In the last 90 days, Pyxis Oncology, Inc. insiders filed 0 open-market purchases and 1 sale; 76 institutions reported holding it in 13F filings for Q2 2026, worth $101.1M in total; no superinvestor holds it.
13F holders, Q3 2022
Institutional positions in Pyxis Oncology, Inc. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 38
- −1 vs. Q2 2022
- Shares held
- 19.4M
- −590.2K (−2.9%) vs. Q2 2022
- Total value
- $38.3M
- −$9.38M (−19.7%) vs. Q2 2022
- New holders
- 5
- 13 more added
- Sold out
- 6
- 8 more reduced
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PYXS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 76 | $101.1M |
| Q1 2026 | 78 | $40.5M |
| Q4 2025 | 79 | $34.7M |
| Q3 2025 | 73 | $59.7M |
| Q2 2025 | 74 | $30.2M |
| Q1 2025 | 89 | $29.6M |
| Q4 2024 | 99 | $49.2M |
| Q3 2024 | 92 | $102.3M |
| Q2 2024 | 80 | $93.1M |
| Q1 2024 | 71 | $97.7M |
| Q4 2023 | 51 | $15.8M |
| Q3 2023 | 54 | $15.4M |
| Q2 2023 | 48 | $24.6M |
| Q1 2023 | 47 | $41.5M |
| Q4 2022 | 31 | $26.5M |
| Q3 2022 | 38 | $38.3M |
| Q2 2022 | 39 | $47.7M |
| Q1 2022 | 45 | $76.1M |
| Q4 2021 | 51 | $199.9M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Pyxis Oncology, Inc.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| UBS Group AG | 155 | $0 | 0.00% | −212−57.8% | Reduced |
| Wells Fargo & Company | 146 | $0 | 0.00% | +76+108.6% | Added |
| Royal Bank of Canada | 192 | $0 | 0.00% | +192 | New |
| FMR LLC | 855 | $2.00K | 0.00% | −3−0.3% | Reduced |
| Two Sigma Advisers, LP | 10,400 | $20.0K | 0.00% | +10,400 | New |
| Prelude Capital Management, LLC | 11,052 | $22.0K | 0.00% | +11,052 | New |
| Tudor Investment Corp Et Al | 13,624 | $27.0K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 15,736 | $31.0K | 0.00% | +12,676+414.2% | Added |
| Charles Schwab Investment Management Inc | 17,739 | $35.0K | 0.00% | +17,739 | New |
| Bank of America Corp | 20,085 | $40.0K | 0.00% | +4,353+27.7% | Added |
| Acadian Asset Management LLC | 23,843 | $46.0K | 0.00% | 00.0% | Unchanged |
| Deutsche Bank AG | 25,000 | $49.0K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 26,398 | $52.0K | 0.00% | +8,656+48.8% | Added |
| State Street Corp | 30,989 | $61.0K | 0.00% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 37,677 | $74.0K | 0.00% | −4,619−10.9% | Reduced |
| Millennium Management LLC | 89,838 | $177.0K | 0.00% | −52,977−37.1% | Reduced |
| Bridgeway Capital Management, LLC | 120,295 | $237.0K | 0.01% | +50,000+71.1% | Added |
| Morgan Stanley | 122,000 | $240.0K | 0.00% | −14,877−10.9% | Reduced |
| Renaissance Technologies LLC | 128,802 | $254.0K | 0.00% | +53,431+70.9% | Added |
| Credit Suisse AG | 152,018 | $299.0K | 0.00% | −813,447−84.3% | Reduced |
| Geode Capital Management, LLC | 188,821 | $371.0K | 0.00% | +78,974+71.9% | Added |
| BlackRock Inc. | 206,554 | $406.0K | 0.00% | +1,250+0.6% | Added |
| Logos Global Management LP | 220,434 | $434.0K | 0.05% | 00.0% | Unchanged |
| Citigroup Inc | 312,308 | $615.0K | 0.00% | −1030.0% | Reduced |
| Cormorant Asset Management, LP | 668,855 | $1.32M | 0.09% | +10.0% | Added |
| Acuta Capital Partners, LLC | 669,158 | $1.32M | 0.59% | +24,009+3.7% | Added |
| Tekla Capital Management LLC | 708,303 | $1.40M | 0.06% | 00.0% | Unchanged |
| Ra Capital Management, L.P. | 764,653 | $1.51M | 0.03% | −188,740−19.8% | Reduced |
| HHLR Advisors, Ltd.SuperinvestorHHLR Advisors (Hillhouse) | 764,406 | $1.51M | 0.04% | 00.0% | Unchanged |
| Newtyn Management, LLC | 800,000 | $1.58M | 0.35% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 848,252 | $1.67M | 0.03% | +848,252 | New |
| Vanguard Group Inc | 917,384 | $1.81M | 0.00% | +68,304+8.0% | Added |
| Barclays PLC | 947,651 | $1.87M | 0.00% | 00.0% | Unchanged |
| Tang Capital Management LLC | 1,411,569 | $2.78M | 0.34% | +32,489+2.4% | Added |
| Perceptive Advisors LLC | 1,528,812 | $3.01M | 0.09% | 00.0% | Unchanged |
| Citadel Advisors LLC | 1,530,785 | $3.02M | 0.00% | +9,849+0.6% | Added |
| BVF Inc | 2,938,851 | $5.79M | 0.24% | 00.0% | Unchanged |
| Laurion Capital Management LP | 3,170,803 | $6.25M | 0.17% | 00.0% | Unchanged |
| RTW Investments, LP | 0 | $0 | 0.00% | −682,220−100.0% | Sold out |
| Ergoteles LLC | 0 | $0 | 0.00% | −36,415−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −14,466−100.0% | Sold out |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −12,882−100.0% | Sold out |
| Legal & General Group Plc | 0 | $0 | 0.00% | −833−100.0% | Sold out |
| New York State Common Retirement Fund | 0 | $0 | 0.00% | −108−100.0% | Sold out |